BPC-157 FDA Approval Status: The Short Answer Here's the bottom line: BPC-157 isn't FDA-approved for any indication
Recombinant proteins engineered with an N-terminal or C-terminal GST tag selectively bind to the immobilized glutathione ligand while most endogenous proteins are removed during washing
Its unique mechanism of action involves modulating immune responses, promoting tissue repair, and protecting neural tissue, making it particularly relevant for diseases ranging from neurodegenerative conditions to metabolic disorders
Sources: FDA Insulin Syringe Standard (ISO 8537) U-100 concentration basis DailyMed: Bacteriostatic Water for Injection 0.9% benzyl alcohol preservative DailyMed: Sterile Water for Injection preservative-free, single-dose CDC Injection Safety multi-dose vial and solvent guidance Peptide Calculator FAQ Visible calculator questions supporting the unit-conversion queries this page targets
In aged rat models, treatment increased activity of antioxidant enzymes like superoxide dismutase (SOD), glutathione peroxidase, and glutathione-S-transferase, improving overall oxidative defense
Your health history, goals, medications, and eligibility are reviewed